Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Regeneron Pharmaceuticals, Inc. is a pharmaceutical and biotechnology company that focuses on researching and developing treatments. Its products treat metabolic and heart diseases, infectious diseases, inflammation, cancers, and more.

Ticker: REGN

Humankind Value: $152.1 B

Revenue: $9.4 B

Market Cap: $72.4 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. Regeneron Pharmaceuticals has earned a spot in our top 100, an outcome largely driven by its work on Healthcare R&D ($114.1 B) and Pharmaceuticals ($33.7 B) and its Economic Value ($3.6 B). The added value we associate with this company’s Healthcare R&D and Pharmaceuticals contains the impact of an estimated 3,067,546.7 additional years lived by people worldwide. It adds economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. However, there is room for improvement in the areas of Greenhouse Gases (-$708.6 M) and Air Pollution (-$148.9 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings